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version and thereby shortens the duration of atrial fibrillation, may 
decrease hemorrhagic complications and appears to be as safe as 
conventional therapy. 
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Long-Term Clinical Benefit of 
Dynamic Cardiomyoplasty 
In their recent report, Jondeau et al. (1) conclude that alterations in
left ventricular diastolic rather than systolic function may be respon- 
sible for the long-term clinical benefits of dynamic ardiomyoplasty. 
They reached this conclusion from evaluation of the short-term effect 
of briefly discontinuing latissimus dorsi muscle stimulation in 10 
patients with heart failure undergoing palliation with this novel 
surgical approach. 
There are several proposed mechanisms advanced concerning the 
long-term clinical benefits witnessed in80% of patients who underwent 
successful dynamic ardiomyoplasty. A myocardial-sparing effect sec- 
ondary to reduced myocardial stress is consistent with the Laplace 
relation in which the thickness of the wall of a sphere is inversely 
related to wall stress when intracavitary pressure and radius remain 
constant. Hence, cardiomyoplasty is likened to ventricular hypertro- 
phy--a physiologic adaptational response to reduce wall stress, thereby 
improving function (2). Ventricular remodeling and delay of further 
ventricular dilation by a girdling effect has also been advanced by 
Capouya et al. (3). After 1-year follow-up, the Food and Drug 
Administration phase II clinical trials continue to show an improve- 
ment in postoperative systolic function, although the absolute in- 
creases remain modest, and to date there is no important difference 
between exercise tolerance and peak oxygen consumption (4). 
The issue of diastolic function has been more difficult to resolve in 
patients after cardiomyoplasty. The contribution of the relaxation 
properties of the overlying muscular envelope may confound this 
assessment. 
We do know that discordant timing of skeletal muscle contraction 
may interfere with diastolic ventricular filling or aggravate mitral 
regurgitation; particularly, in patients with ventricular conduction 
delays. Therefore, burst frequency, burst duration and synchronizing 
delay period (the time between R wave sensing and the onset of burst 
stimulation) may loom large when evaluating diastolic function. 
Three modes of selecting the delay period for the burst stimulation 
in dynamic ardiomyoplasty have been described by Helou et al. (5) in 
Montreal. In the fixed time mode, the synchronizing delay period is 
fixed at 25 ms, which corresponds to the usual time interval between 
the R wave and the onset of mechanical cardiac systole in patients with 
normal conduction. In patients with bundle branch block and other 
conduction delays, skeletal muscle contraction around the heart may 
occur in late diastole before closure of the mitral valve and before 
mechanical cardiac systole. To avoid this situation, two-dimensional 
echocardiography is used to time the onset of burst stimulation with 
mitral valve closure in the valve-synchronized mode. This approach 
ensures that burst stimulation is delivered at the onset of mechanical 
cardiac systole. The flow-optimized mode maximizes stroke volume and 
cardiac output by timing the onset of burst stimulation i the isovolu- 
mic contraction period to achieve maximal aortic flow velocity. 
The authors of this study used the valve-synchronized mode for 
establishing the appropriate synchronization delay in each patient. 
Three patients (30%) were excluded from the Doppler study of mitral 
flow because of important mitral regurgitation. What was the preop- 
erative status and function of the mitral valve in their 10 patients? Did 
subsequent performance of dynamic ardiomyoplasty exacerbate mi- 
tral regurgitation? Were the postoperative diastolic function studies 
presented in their report done preoperatively? If so, how does the 
preoperative diastolic function compare with the postoperative func- 
tion--cardiomyostimulator "on"and "off"? 
Inferences from data obtained from acute "on" and "off,' studies 
with the cardiomyostimulator for periods ->1 h may have inherent 
flaws because the wealth of clinical experience suggests that the 
potential salutary benefits of dynamic ardiomyoplasty take several 
months to manifest, implicating conformational, daptive and remod- 
eling mechanisms. It would be interesting torepeat hese studies with 
the cardiomyostimulator turned off for several months. 
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